Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025

NORWOOD, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today announced that it will host an in-person and virtual KOL event at the European Society for Medical Oncology (ESMO) Congress 2025 to review and discuss dose optimization data from its Phase 1/2 clinical study of CRB-701 (SYS6002). Data from over 100 participants with either head and neck squamous cell carcinoma (HNSCC), cervical, or metastatic urothelial tumors will be presented.

Read more at globenewswire.com